#16
|
|||
|
|||
ò.å. äëÿ âûÿñíåíèÿ ïðè÷èíû ãèïîõðîìíîé, ìèêðîöèòàðíîé àíåìèè íàäî ñäåëàòü ìàçîê...
è íàçíà÷àòü ïðåïàðàòû æåëåçà â ýòîì ñëó÷àå, êîíå÷íî, íåëüçÿ? Âàäèì Âàëåðüåâè÷, åñëè áóäåò ïàöèåíòêà çà 40 ëåò ñ ãèïîõðîìíîé, ìèêðîöèòàðíîé àíåìèåé (è àíàëèç ñäåëàí àâòîìàòè÷åñêè - ò.å. äðóãèõ ïðèçíàêîâ íåò), ìîæíî ïðîáíî íàçíà÷èòü Â6? |
#17
|
||||
|
||||
ïèðèäîêñèí-äåôèöèòíàÿ àíåìèÿ ãîðàçäî ðåæå ïðèêëþ÷àåòñÿ, ÷åì æåëåçîäåôèöèòíàÿ, ïîýòîìó åñëè ó æåíùèíû èìåþòñÿ è äð. æåëåçîäåôèöèòíûå æàëîáû èëè ïðîÿâëåíèÿ http://forums.rusmedserv.com/showthread.php?t=30256, òî ìîæíî íàçíà÷èòü ïðîáíîå ëå÷åíèå Fe, åñëè ÷åðåç ìåñÿö óëó÷øåíèé íåò è ïî àíàëèçàì, òî íåîáõîäèìî âûïîëíèòü äîï. ëàá. èññëåäîâàíèÿ (ôåððèòèí, æåëåçî, îæññ) äëÿ óòî÷íåíèÿ, äåéñòâèòåëüíî ëè ýòà àíåìèÿ ÆÄ èëè. äð. ãåíåçà. Âî âñåõ îñòàëüíûõ ñëó÷àÿõ (ìóæ÷èíû èëè æåíùèíû ïðåêëîííîãî âîçðàñòà) ïðè âûÿâëåíèè àíåìèè íåîáõîäèìû äîï. ëàá. èññëåäîâàíèÿ äëÿ óñòàíîâëåíèÿ ãåíåçà.
__________________
Èñêðåííå, Âàäèì Âàëåðüåâè÷. |
#18
|
|||
|
|||
Ñïàñèáî çà ïîäðîáíûå îòâåòû.
Íàäåþñü, íå óòîìèëà Âàñ? Åù¸ îäèí âîïðîñ...  ñëó÷àå äåôèöèòà ãåìà, ñâÿçàííîãî ñ äåôèöèòîì ãëèöèíà, òîæå ðàçâèâàåòñÿ ÆÄÀ? Êàê îòëè÷èòü ýòó àíåìèþ? |
#19
|
||||
|
||||
Ïîõîæå, ÷òî òàêîé àíåìèè íå áûâàåò, ðàâíî êàê è äåôèöèòà ãëèöèíà â îðãàíèçìå. Åñëè Âû èìåëè ââèäó ïðèìåíåíèå õåëàòíûõ ôîðì æåëåçà ñ ãëèöèíîì, òî åòî ñâÿçàíî ñ åãî ëó÷øåé óñâîÿåìîñòüþ, ïî ñðàâíåíèþ ñ ñóëüôàòîì æåëåçà:
Iron amino acid chelates, such as iron glycinate chelates, have been developed to be used as food fortificants and therapeutic agents in the prevention and treatment of iron deficiency anemia. Ferrous bis-glycine chelate (FeBC), ferric tris-glycine chelate, ferric glycinate, and ferrous bis-glycinate hydrochloride are available commercially. FeBC is the most studied and used form. Iron absorption from FeBC is affected by enhancers and inhibitors of iron absorption, but to a lesser extent than ferrous sulfate. Its absorption is regulated by iron stores. FeBC is better absorbed from milk, wheat, whole maize flour, and precooked corn flour than is ferrous sulfate. Supplementation trials have demonstrated that FeBC is efficacious in treating iron deficiency anemia. Consumption of FeBC-fortified liquid milk, dairy products, wheat rolls, and multi-nutrient beverages is associated with an improvement of iron status. (Int J Vitam Nutr Res. 2004 Nov;74(6):435-43)
__________________
Èñêðåííå, Âàäèì Âàëåðüåâè÷. |
#20
|
|||
|
|||
ß íàøëà òàêóþ ñõåìó:
ãëèöèí-----ãàììà-àìèíîëåâóëîíîâàÿ ê-òà ------ïîðôîáèëèíîãåí------êîïðîïîðôîáèëèíîãåí-------ïðîòîïîðôèðèí------- Fe + ãåìñèíòåòàçà. Âàäèì Âàëåðüåâè÷, ìîæåò ëè ïðè ëàòåíòíîì äåôèöèòå æåëåçà áûòü òàêàÿ æàëîáà: "ãëàçà áîëÿò" |
#21
|
||||
|
||||
Âñå âåðíî: ãëèöèí è ñóêöèíèë-ÊîÀ ó÷àñòâóþò â íàðàáîòêå àìèíîëåâóëîíîâîé ê-òû, íî äåôåêò áûâàåò çäåñü íå â äåôèöèòå ãëèöèíà, à â íèçêîé àêòèâíîñòè èìåííî ãëàâíîãî ôåðìåíòà àìèíîëåâóëèíàò-ñèíòàçû, êîòîðàÿ ÿâëÿåòñÿ ïèðèäîêñèí-çàâèñèìîé (è èíîãäà ïðè èçáûòêå Â6 óäàåòñÿ àêòèâèçèðîâàòü ýòîò ôåðìåíò).
Íåò, òàêîé æàëîáû ìíå íåèçâåñòíî.
__________________
Èñêðåííå, Âàäèì Âàëåðüåâè÷. |
#22
|
|||
|
|||
Åñòü ëè ñâÿçü ìåæäó "íèçêèì" ãåìîãëîáèíîì è ãèïîòîíèåé?
(÷àñòî ïðèõîäèòüñÿ ñëûøàòü: äàâëåíèå íèçêîå - ïðîâåðü ãåìîãëîáèí). è ìîæåò ëè àíåìèÿ áûòü ïðè÷èíîé âîçíèêíîâåíèÿ îò¸êîâ? |
|
#23
|
||||
|
||||
Ó æåíùèí ñ äëèòåëüíîé ÆÄÀ ìîæåò áûòü ñêëîííîñòü ê ãèïîòîíèè è òàõèêàðäèÿì, òåîðåòè÷åñêè ïðè ÆÄ ïîâûøàåòñÿ ïðîíèöàåìîñòü ñîñóäèñòîé ñòåíêè, íî ýòî íå ïðèâîäèò ê ìàññèâíûì îòåêàì
__________________
Èñêðåííå, Âàäèì Âàëåðüåâè÷. |
#24
|
|||
|
|||
Ó ìåíÿ ïàöèåíòêà ñ îðòîñòàòè÷åñêîé ãèïîòîíèåé (ïîñëå ãîðèçîíòàëüíîãî ïîëîæåíèÿ îíà ïûòàëàñü ñåñòü , è ó íåå ñèëüíî çàêðóæèëàñü ãîëîâà).
Ìîæåò ëè áûòü ýòî ñâÿçàíî ñ òàêèì àíàëèçîì. (îñòàëüíîå - â íîðìå). êîë-âî ëåéêîöèòîâ Õ10 9/ë (4.0-10.0 ) 7.3 êîë-âî ýðèòðîöèòîâ Õ10 12/ë (3.5-5.2) 4.95 Hgb ã/äë (12.0-15.0) 11.7 HCT ãåìàòîêðèò 38.1 MCV ñðåäíèé îáúåì ýðèòðîöèòà ôë (80.0-103.0) 76.9 ÌÑÍ ïã (26.5-33.5) 23.6 ÌÑÍÑ ã/äë (30.0-36.0) 30.7 |
#25
|
||||
|
||||
Ó ïàöèåíòêè èìååòñÿ àíåìèÿ ëåãêîé ñòåïåíè (ãåìîãëîáèí ó æåíùèí â íîðìå îò 122-123 è âûøå)ïî õàðàêòåðó ìèêðîöèòàðíàÿ è ãèïîõðîìíàÿ (âåðîÿòíî æåëåçîäåôèöèòíàÿ: èññëåäîâàòü æåëåçî, îæññ, ôåððèòèí), òàê ÷òî îðòîñòàòè÷åñêàÿ ãèïîòåíçèÿ ó íåå âïîëíå ìîæåò áûòü èç-çà àíåìèè.
__________________
Èñêðåííå, Âàäèì Âàëåðüåâè÷. |
#26
|
|||
|
|||
Âàäèì Âàëåðüåâè÷, ìîãëè Âû äàòü ññûëêè ïî ÑÎÝ, ò.å. àëãîðèòìû äàëüíåéøåãî îáñëåäîâàíèÿ ïðè âûñîêèõ ÑÎÝ?
Ó ìîåé ïàöèåíòêè ÑÎÝ-50 + íèçêèé ãåìîãëîáèí è âñ¸. ïðîâåðþ åé ÑÐÁ (ìîæíî ëè ïî íåìó ñóäèòü åñòü èëè íåò îíêîëîãè÷.çàáîëåâàíèå?) è ÀÍÀ. |
#27
|
||||
|
||||
Ê ñîæàëåíèþ, òîëüêî íà àíãëèéñêîì:
Clinical utility of the erythrocyte sedimentation rate [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
__________________
Èñêðåííå, Âàäèì Âàëåðüåâè÷. |
#28
|
|||
|
|||
Ñïàñèáî. Óñòðàèâàåò âïîëíå.
|
#29
|
|||
|
|||
Âàäèì Âàëåðüåâè÷, çäðàâñòâóéòå.
õî÷ó ñïðîñèòü ïðî êîàãóëîãðàììó... Ïî êàêèì ïîêàçàíèÿì íàäî îïðåäåëÿòü ïðîòðîìáèíîâûé èíäåêñ è âðåìÿ ñâåðòûâàíèÿ (÷èòàëà, ÷òî ïðîòðîìáèíîâûé èíäåêñ íå ÿâëÿåòñÿ ïîêàçàíèåì äëÿ íàçíà÷åíèÿ àñïèðèíà êàðäèî? òåïåðü íå âðåìÿ ñâåðòûâàíèÿ, à ÌÍÎ è À×Ò ïðîâåðÿþò ïàöèåíòû, êîò. äåëàþò èíúåêöèè ãåïàðèíà). È âîîáùå êàêèå èìåííî àíàëèçû èç êîàãóëîãðàììû íà ñåãîäíÿøíèé äåíü óæå óòðàòèëè ñìûñë? |
#30
|
||||
|
||||
Ïîñìîòðèòå ïîæàëóéñòà ñòðàíèöû 16-17-18 ïî åòîé ññûëêå, åñëè îñòàíóòñÿ âîïðîñû - çàäàâàéòå:
[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
__________________
Èñêðåííå, Âàäèì Âàëåðüåâè÷. |